Dr. Kindler has always been interested in finding a cure for mesothelioma, but losing her father to the disease in 2001 increased her desire to find a successful curative treatment, while also improving the connection she feels with each of her patients and their family.
Hedy Lee Kindler, M.D., has devoted her career to the study and treatment of mesothelioma cancer, a career which puts her in close contact with more than 100 mesothelioma patients from all over the world each year. Not only is her knowledge prized by her patients, but other doctors frequently turn to Dr. Kindler for advice about mesothelioma patients they’re working with.
Dr. Kindler’s work in the study of treatments for mesothelioma has made her a leading expert in her field of study. She’s frequently asked to speak about mesothelioma at events. In addition to mesothelioma, Dr. Kindler also works to find a treatment for both gastrointestinal stromal tumors and pancreatic cancer.
The treatment programs Dr. Kindler has been involved with have been focused on the use of drugs such as Alimta and gemcitabine.
Medical Degree and Residency
In 1989, Dr. Kindler graduated with her medical degree from the State University of New York Buffalo. She left Buffalo to travel to California where she spent her residency at UCLA Medical Center Internal Medicine. She completed the residency program in 1991.
Dr. Kindler serves as the Assistant Professor of Medicine at the University of Chicago Medical Center.
Dr. Kindler’s Accomplishments
Throughout the course of her illustrious career, Dr. Kindler has been a leader of clinical trials that have explored various ways to treat mesothelioma cancer. Her work and dedication to each of the patients she works with has done wonders to not only extend their life but also improve the quality of their life. Her reputation attracts patients from all over the world.
Dr. Kindler is an active member of several cancer organizations, including:
- American Association for Cancer Research
- The Mesothelioma Applied Research Foundation
- The International Association for the Study of Lung Cancer
- The American Society of Clinical Oncology
- The International Mesothelioma Interest Group
In 2002, Dr. Kindler generated a great deal of interest from the medical community when she published an article titled The Role of Gemcitabine in the Treatment of Mesothelioma. Dr. Kindler used the article to educate her fellow doctors about the idea that gemcitabine, a drug used for chemotherapy, helps extend and improve the lives of patients with mesothelioma. She feels that gemcitabine should be used in tandem with other drugs such as Pemetrexed, Bevacizumab, and Vinorelbine.
Another article penned by Dr. Kindler, Moving Beyond Chemotherapy: novel cytostatic agents for malignant mesothelioma, gave detailed evaluations about drugs such as Bevacizumab as a means for blocking signaling pathways and slowing mesothelioma cell growth. More than 10 years later, doctors still site this article and credit the information with helping them extend the life of mesothelioma patients.
From 2006-2010, Dr. Kindler spent two terms as the International Mesothelioma Interest Group president. She’s currently an associate editor for Lung Cancer, a highly respected medical journal.
Dr. Kindler’s Clinical Research
When it comes to clinical research, Dr. Kindler goes right to the heart of mesothelioma research and has been the driving force behind many clinical trials that have been focused on novel treatments.
Her work, intelligence, experience, and determination to find a cure has helped develop highly personalized treatment options that have resulted in a positive patient response.
You can learn more about Dr. Kindler, her treatment methods, and other specialists in our free Mesothelioma Survivors Guide.